Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bristol-Myers Squibb Co BMY

Healthcare
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule... see more

Recent & Breaking News (NYSE:BMY)

Safety Data for Lirilumab in Combination with Nivolumab or Ipilimumab Announced at ESMO 2016 Congress

Business Wire October 9, 2016

Bristol-Myers Squibb Presents Results From CheckMate -026, a Phase 3 Study of Opdivo (nivolumab) Monotherapy Versus Chemotherapy as First-Line Therapy in a Broad PD-L1 Positive Population With Advanced Lung Cancer

Business Wire October 9, 2016

Opdivo (nivolumab) Stabilized Patient-reported Outcomes in Patients With Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck in Pivotal Phase 3 CheckMate -141 Study

Business Wire October 9, 2016

Results From CheckMate-275 Validate Further Study of Opdivo (nivolumab) in Patients With Advanced Form of Bladder Cancer

Business Wire October 8, 2016

Yervoy (ipilimumab) Improves Overall Survival in Fully Resected Stage III Melanoma Patients From Phase 3 Study

Business Wire October 8, 2016

Covered Call reports for Bristol-Myers Squibb, Whole Foods Market, Alcoa, The Kroger Co and The Home Depot Inc. include trade ideas that offer returns of 20% or more!

PR Newswire October 7, 2016

New Research From Bristol-Myers Squibb at ESMO 2016 Congress Reinforces Leadership in Immuno-Oncology and Differentiated Research Approach

Business Wire October 3, 2016

Bristol-Myers Squibb and Nektar Therapeutics Announce Oncology Clinical Collaboration to Evaluate the Combination of Opdivo (nivolumab) and NKTR-214

Business Wire September 27, 2016

Covered Call reports for Bristol-Myers Squibb, First Solar, Corrections Corporation of America, PayPal Holdings Inc. and Walgreens Boots Alliance include trade ideas that offer returns of 20% or more!

PR Newswire September 23, 2016

Bristol-Myers Squibb to Take Part in Leerink Partners Immuno-Oncology Roundtable Conference

Business Wire September 22, 2016

European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) in Advanced Form of Bladder Cancer

Business Wire September 20, 2016

Bristol-Myers Squibb Awards First “Golden Tickets” for LabCentral to PanTher, Suono Bio

Business Wire September 20, 2016

Seattle Genetics No Longer On Goldman Sachs' Sell List

Benzinga.com  September 15, 2016

Bristol-Myers Squibb to Announce Results for Third Quarter 2016 on October 27

Business Wire September 7, 2016

Bristol-Myers Squibb to Present at Bank of America Merrill Lynch Global Health Care Conference

Business Wire September 7, 2016

Bristol-Myers Squibb Employees Cycle Coast to Coast to Raise Money and Awareness for Cancer Research

Business Wire September 7, 2016

Retail Investors Loved Beat Up Stocks In August

Benzinga.com  September 6, 2016

Investor Movement Index (IMX) for August 2016

Benzinga.com  September 6, 2016

Bristol-Myers Squibb to Take Part in Morgan Stanley Global Health Care Conference

Business Wire September 6, 2016

European Commission Approves Bristol-Myers Squibb’s ORENCIA® (abatacept) for the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis Not Previously Treated with Methotrexate

Business Wire September 6, 2016